Morgan Stanley Maintains Sophia Genetics(SOPH.US) With Hold Rating, Maintains Target Price $5
Morgan Stanley Sticks to Its Hold Rating for SOPHiA GENETICS (SOPH)
RBC Capital Maintains Sophia Genetics(SOPH.US) With Buy Rating, Maintains Target Price $7
SOPHiA GENETICS: Strong Buy Rating Amidst Promising Growth Prospects and Financial Stability
TD Cowen Maintains Sophia Genetics(SOPH.US) With Buy Rating
RBC Capital Maintains Sophia Genetics(SOPH.US) With Buy Rating, Maintains Target Price $7
RBC Capital Keeps Their Buy Rating on SOPHiA GENETICS (SOPH)
TD Cowen Maintains Sophia Genetics(SOPH.US) With Buy Rating
Sophia Genetics Analyst Ratings
RBC Capital Maintains Outperform on Sophia Genetics, Lowers Price Target to $7
Morgan Stanley Downgrades SOPHiA GENETICS to Equal Weight From Overweight, Adjusts Price Target to $5 From $10
Hold Rating on SOPHiA GENETICS Amidst Q2 Revenue Shortfall and Balanced Risk/Reward Outlook
RBC Capital Remains a Buy on SOPHiA GENETICS (SOPH)
TD Cowen Maintains Sophia Genetics(SOPH.US) With Buy Rating
TD Cowen Sticks to Their Buy Rating for SOPHiA GENETICS (SOPH)
Sophia Genetics Analyst Ratings
Guggenheim Initiates Coverage On Sophia Genetics With Buy Rating, Announces Price Target of $6
Analysts Offer Insights on Healthcare Companies: Inari Medical (NARI), Biogen (BIIB) and SOPHiA GENETICS (SOPH)
RBC Capital Remains a Buy on SOPHiA GENETICS (SOPH)
SOPHiA GENETICS (SOPH) Gets a Buy From RBC Capital